glp-1 receptor agonists in pediatric and adolescent obesity diabetes: a systematic review of efficacy, metabolic effects, and safety GLP-1 agonists in pediatric obesity:

[DOI] [PubMed] [Google Scholar] 64.Ridker PM, et al

Of note, this approach to ICP monitoring was chosen by the patient advisory group due to the negative impact reported by repeated lumbar punctures [23, 24], and the use within the trial was carefully discussed with the individual participants during the consent process

Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial

Macrophage polarization in pathology

Liraglutide was approved by the FDA for marketing in the United States in 2010 and officially launched in China in 2011

Anti-inflammatory effects of GLP-1 in patients with COVID-19